Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
NCT00088933
Terminated
This randomized phase I trial studies the side effects, best way to give, and best dose of docetaxel when given together with vaccine therapy and sargramostim in treating patients with metastatic lung cancer or metastatic colorectal cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow and peripheral blood. Drugs used in chemotherapy, such as docetaxel, work in diff... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2014
Locations: Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia
Conditions: Extensive Stage Small Cell Lung Cancer, Recurrent Colon Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Rectal Cancer, Recurrent Small Cell Lung Cancer, Stage IV Colon Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Rectal Cancer
Register for Updates
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)
NCT01691326
Completed
The aim of this clinical study is to demonstrate safety and immunogenicity of Fluzone vaccine. Objective: * To describe the safety of the 2012-2013 formulation of Fluzone vaccine, administered in a 1- or 2-dose schedule, in accordance with Advisory Committee on Immunization Practices (ACIP) recommendations, in children 6 months to \< 9 years of age. Observational Objectives: * To describe the immunogenicity of the 2012-2013 formulation of Fluzone vaccine, administered in a 1- or 2-dose sched... Read More
Gender:
ALL
Ages:
Between 6 months and 8 years
Trial Updated:
03/12/2014
Locations: Not set, Bardstown, Kentucky +1 locations
Conditions: Influenza
Register for Updates
Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years
NCT01706367
Completed
This is a first-in-human study (phase 1) of a 3-dose vaccination regimen with one of three dose levels of C difficile vaccine with or without adjuvant in healthy adults aged 50 to 85 years. The main goal of the study is to determine how safe and well-tolerated the vaccine is. In addition, the study aims to assess the immune response to the C difficile vaccine.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/05/2014
Locations: Pfizer Investigational Site, Pembroke Pines, Florida +3 locations
Conditions: Clostridium Difficile Associated Disease
Register for Updates
RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly
NCT01709019
Completed
Up to 220 eligible subjects will be enrolled into one of five treatment groups. It is anticipated that some of the randomized study subjects may not complete the study; subjects who withdraw or are discontinued, will not be replaced. Randomization will be stratified by age (60 to \<75 years and ≥ 75 years) in order to distribute the proportion of such persons in each age group equally across treatment groups. Treatments will comprise a single IM dose of a placebo or RSV-F protein nanoparticle v... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/04/2014
Locations: Genova Clinical Research, Tucson, Arizona +3 locations
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting
NCT01184079
Completed
The investigators propose a randomized, open label trial of the immunogenicity of HPV vaccine among males 18-24 years old, comparing an on-time administration of the third dose with delayed administration of the third dose. All participants would receive the first and second doses according to schedule. They would be randomized to either Dose 3 at 6 months or Dose 3 at 12 months. Hypothesis: The Geometric mean titers in the 12 month test group (T) are non-inferior to the usual timing control gr... Read More
Gender:
MALE
Ages:
Between 18 years and 26 years
Trial Updated:
02/26/2014
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Quadrivalent HPV Vaccine, Human Papillomavirus Vaccine
Register for Updates
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants
NCT00474526
Completed
This study will evaluate the safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants.
Gender:
ALL
Ages:
Between 2 months and 2 months
Trial Updated:
02/24/2014
Locations: Growing Up Pediatrics, Bessemer, Alabama +62 locations
Conditions: Meningitis, Meningococcal
Register for Updates
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
NCT00953524
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after each injection. * To describe the safety of the candidate vaccines after each injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2014
Locations: Not set, Hoover, Alabama +14 locations
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
RSV-F Vaccine Dose Ranging Study in Young Women
NCT01704365
Completed
The purpose of this study is to evaluate the immunogenicty and safety of an RSV-F protein nanoparticle vaccine, with out without aluminum, in healthy women of child-bearing potential.
Gender:
FEMALE
Ages:
Between 18 years and 35 years
Trial Updated:
02/05/2014
Locations: Anaheim Clinical Trials, Anaheim, California +3 locations
Conditions: Respiratory Syncytial Virus (RSV)
Register for Updates
Improving the Efficacy of Anti-Nicotine Immunotherapy
NCT01280968
Completed
The purpose of this study is to find out how vaccine-induced antibodies change the way the body processes nicotine from cigarettes. These antibodies absorb nicotine and can reduce nicotine levels in the brain. In this way, the vaccination may help to quit smoking. The central hypothesis is that anti-nicotine antibodies change kinetics of brain nicotine accumulation and distribution of nicotine between the brain and other body tissues. This vaccine is investigational which means that it is still... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/29/2014
Locations: Duke Center for Nicotine & Smoking Cessation Research, Durham, North Carolina +1 locations
Conditions: Nicotine Dependence
Register for Updates
Study of Intradermal Administration of PCEC Rabies Vaccine
NCT01044199
Completed
The purpose of this study is to determine immunogenicity and safety of intradermal administration of the PCEC rabies vaccine in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2014
Locations: CDC Occupational Clinic, Atlanta, Georgia
Conditions: Rabies Prevention, Rabies Exposure
Register for Updates
Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine
NCT00772070
Completed
This study was designed to simulate meningococcal challenge by vaccination with a fractional combined dose of unconjugated meningococcal polysaccharides A, C, Y, and W-135, Menomune® in children who were vaccinated with one dose of TetraMenD at least 18 months earlier. Primary Objective: To evaluate and compare the antibody responses to a reduced dose of Menomune® in participants who had previously received a tetravalent meningococcal diphtheria toxoid conjugate vaccine to those responses in p... Read More
Gender:
ALL
Ages:
Between 3 years and 5 years
Trial Updated:
01/21/2014
Locations: Not set, Jonesboro, Arkansas +7 locations
Conditions: Meningitis, Meningococcemia, Neisseria Meningitidis
Register for Updates
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
NCT00258856
Completed
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02. In addition, the kinetics of the antibody response will be evaluated in a subset of participants who will receive a booster dose of Menactra® vaccine and children in the same age group not previously vaccinated with a meningococcal vaccine or had meningitis disease who will receive a dose of Menactra® vaccine... Read More
Gender:
ALL
Ages:
Between 7 years and 15 years
Trial Updated:
01/21/2014
Locations: Not set, Jonesboro, Arkansas +10 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates